Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
The conference is taking place at the Ritz Carlton Hotel in Dana Point, California March 9-12, 2014 and is one of the largest of its kind, attended by numerous emerging growth companies and their investors. Company presentations, Q&A sessions, panels and management one-on-one meetings offer investor clients opportunities for extensive interaction with executive management to gain in-depth insights into each business and sector.
Glynn Wilson, Ph.D., Chief Executive Officer, will present at 12:00pm PST on Wednesday March 12th. Dr Wilson will cover recent corporate events including the positive interim results from its lead clinical program in Her2/neu+ breast cancer at the Mayo Clinic, Rochester MN.
At the Conference, there will be an opportunity for investors to meet one-on-one with Glynn Wilson and the TapImmune team.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at http://www.tapimmune.com/ for details.
Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Glynn Wilson, PH.D.
Chairman & CEO
Source: TapImmune Inc.
Leave a comment...